Journal article
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects
Abstract
OBJECTIVES: We investigated the acute and long-term hemodynamic and neurohumoral effects of the vasopeptidase inhibitor omapatrilat in human heart failure.
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the treatment of chronic heart failure (CHF). Simultaneous inhibition of both neutral endopeptidase and ACE with omapatrilat may represent a new treatment strategy in CHF.
Authors
McClean DR; Ikram H; Mehta S; Heywood JT; Rousseau MF; Niederman AL; Sequeira RF; Fleck E; Singh SN; Coutu B
Journal
Journal of the American College of Cardiology, Vol. 39, No. 12, pp. 2034–2041
Publisher
Elsevier
Publication Date
6 2002
DOI
10.1016/s0735-1097(02)01881-8
ISSN
0735-1097